A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Phase 1
Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT01136733
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01133990
- Locations
- 🇮🇳
Shatabdi Hospital, Nashik, India
🇮🇳Noble Hospital, Pune, India
🇮🇳Subodh Mitra Cancer Hospital and Research centre, Kolkata, India
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT01133977
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Phase 1
Terminated
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01133756
- Locations
- 🇺🇸
Texas Oncology - Austin Central, Austin, Texas, United States
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Phase 2
Completed
- Conditions
- Stage IIIC MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01127451
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Solid Tumors
- Interventions
- Drug: E7016 + TMZ
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01127178
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01126736
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
Phase 4
Completed
- Conditions
- Sedation
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT01127438
- Locations
- 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Miami Research Associates, South Miami, Florida, United States
🇺🇸Research Associates of New York, LLP, New York, New York, United States
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01126749
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT01111461
© Copyright 2025. All Rights Reserved by MedPath